Bullrally.com - Stocks, Penny Stocks and more...

Stocks at Attractive Levels

raiiden — Fri, 05 Sep 2008 15:47:16 +0000

The markets have taken a beating and the following stocks have come down to an attractive level.

RIMM
V
FSLR
DRYS
EXM
BTU
AGN

SOLF Has Formed a Bullish Candlestick Reversal Pattern

raiiden — Thu, 04 Sep 2008 06:16:05 +0000

Solarfun Power Holdings - SOLF has formed a text book hammer pattern. After a standard down trend, the bottom candle shows that buyers have come back into the markets and reversed the downtrend in one day. This candlestick is the hammer which is shown with the long tail and little body. I believe this one will see some upside here.

RIMM Has retraced near a Fibonacci Level

raiiden — Wed, 03 Sep 2008 04:57:42 +0000

RIMM has come down quite a bit from it’s high and has retraced to near the 61.8% fibonacci support level. I believe it will see some upside here as the release date for the Bold approaches.

OCR and V Still Showing Some Strength

raiiden — Sun, 31 Aug 2008 01:52:18 +0000

V is also showing strength and could see another 1-2 points to the upside.

This one could go higher, stop loss set at $30.27.

Is Neoprobe One to Watch?

raiiden — Tue, 15 Jul 2008 04:50:50 +0000

by Joe J.

NEOP has been publicly traded for 23 years. It has 50% market share in gamma probes, geiger counters that detect cancer during surgeries, so doctors can remove all the cancerous tissue. That’s the “razor”. It’s profitable, except for R&D expenses to develop the “razor blade”. Once you sell the razor, you make a killing selling razor blades for recurring revenues and earnings.

The razor blade is Lymphoseek, a compound that finds the sentinel lymph node during breast cancer surgery, so the doctors can learn if the cancer has spread. This rapidly growing procedure is much less invasive and less costly than removing 20 nodes, or axillary surgery, which removes the side of the breast and the gland under the armpit.

Currently, there is no drug approved to find the sentinel node, so a colloid compound, blue dye, is used off-label, and it’s not reimbursable, so hospitals eat $900 each surgery. Lymphoseek will be first-in-class drug, approvable, and only stays in the body 24 hours, vs. several days for the current drug. It was 99.5% accurate in Phase II trials, and is well into Phase III, which will be completed in 2008. Interim results are expected this quarter, which should really move the stock. Total market potential is $225M/year.

The Company will go from $7M in annual revenues to estimated $50M in 2010, and like all biotechs, the stock will move strongly in anticipation. 70% gross margins, a per-dose fee, and a 5 year contract locked up with the biggest oncology drug distributor in the U.S., Cardinal Health.

NEOP outsources sales, marketing, and distribution, so net profits will be super. Earnings will soar. With spectacular results in Phase II trials, and zero safety issues, there is a very high likelihood Lymphoseek will get approved, with sales starting in Q4-2009. The stock hit a high of $23 in 1996 when it was completing Phase III trials for RIGS, a drug which detects cancer during colorectal surgeries, but wasn’t approved.

Now RIGS is back in gear, due to start new Phase III trials in 2009, with a market potential of $2.5 Billion! Anticipation of it should drive the stock well over $5 and re-listing.

Exit

Genesis — Wed, 11 Jun 2008 15:31:49 +0000

exiting all positions. Exited ATMl and CNP two days ago (Monday), sorry I did not update.